Up­dat­ed: Eli Lil­ly’s tirzepatide re­duces risk of heart fail­ure out­comes in Phase 3 study

Eli Lil­ly has de­clared vic­to­ry in the first late-stage tri­al test­ing tirzepatide’s ef­fect on car­dio­vas­cu­lar out­comes, as it looks to catch up with No­vo Nordisk …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER